Literature DB >> 21319344

Changes in glycogen and glycosaminoglycan levels in hepatocytes of iduronate-2-sulfatase knockout mice before and after recombinant iduronate-2-sulfatase supplementation.

Jee Hyun Lee1, Yon Ho Choe, Su Jin Kim, Kyung Hoon Paik, Dong-Kyu Jin.   

Abstract

PURPOSE: Mucopolysaccharidosis II (MPS II) is a lysosomal storage disorder caused by a deficiency of iduronate-2 sulfatase (IdS), which is involved in the degradation of glycosaminoglycan (GAG). In this study, the frequency of fasting hypoglycemia in patients with MPS II was investigated and changes in accumulation of glycogen and GAG in the hepatocytes of IdS-knockout (KO) mice were evaluated before and after recombinant IdS enzyme replacement therapy (ERT).
MATERIALS AND METHODS: Plasma glucose levels were evaluated after an 8-hour fast in 50 patients with MPS II. The IdS-KO mice were divided into three groups (group 2; saline, group 3; 0.15 mg/kg of IdS, and group 4; 0.5 mg/kg of IdS); wild-type mice were included as controls (group 1). ERT was initiated intravenously at four weeks of age, and continued every week until 20 weeks of age.
RESULTS: The mean glucose level after an 8-hour fast was 94.1 ± 23.7 mg/dL in the patients with MPS II. Two (4%) out of 50 patients had fasting hypoglycemia. For the mice, GAG in the lysosomes nearly disappeared and glycogen particles in the cytoplasm were restored to the normal range in group 4.
CONCLUSION: Glucose metabolism in patients with MPS II appeared to function well despite hepatocytic GAG accumulation and hypothetical glycogen depletion. A higher dose of IdS infusion in MPS II mice led to disappearance of lysosomal GAG and restoration of glycogen to the cytoplasm of hepatocytes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21319344      PMCID: PMC3051226          DOI: 10.3349/ymj.2011.52.2.263

Source DB:  PubMed          Journal:  Yonsei Med J        ISSN: 0513-5796            Impact factor:   2.759


  9 in total

1.  Hepatic fibrosis in the mucopolysaccharidoses.

Authors:  N A Parfrey; G M Hutchins
Journal:  Am J Med       Date:  1986-11       Impact factor: 4.965

2.  A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome).

Authors:  Joseph Muenzer; Muge Gucsavas-Calikoglu; Shawn E McCandless; Thomas J Schuetz; Alan Kimura
Journal:  Mol Genet Metab       Date:  2006-12-20       Impact factor: 4.797

3.  Characterization of a novel mucopolysaccharidosis type II mouse model and recombinant AAV2/8 vector-mediated gene therapy.

Authors:  Sung-Chul Jung; Eun-Sook Park; Eun Nam Choi; Chi Hwa Kim; Su Jin Kim; Dong-Kyu Jin
Journal:  Mol Cells       Date:  2010-07-14       Impact factor: 5.034

4.  An adult case with Hunter's syndrome presenting prominent hepatic failure: light and electron microscopic features of the liver.

Authors:  Tsuyoshi Yoshimoto; Makoto Nakamuta; Kazuhiro Kotoh; Motoyuki Kohjima; Shusuke Morizono; Yuzuru Miyagi; Hironori Sakai; Munechika Enjoji
Journal:  Intern Med       Date:  2006-11-15       Impact factor: 1.271

Review 5.  Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report.

Authors:  J Muenzer; J C Lamsa; A Garcia; J Dacosta; J Garcia; D A Treco
Journal:  Acta Paediatr Suppl       Date:  2002

6.  Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II.

Authors:  Antony R Garcia; Jeffrey M DaCosta; Jing Pan; Joseph Muenzer; Justin C Lamsa
Journal:  Mol Genet Metab       Date:  2007-04-24       Impact factor: 4.797

7.  Light and electron microscopic features of the liver in mucopolysaccharidosis.

Authors:  J M Resnick; C B Whitley; A S Leonard; W Krivit; D C Snover
Journal:  Hum Pathol       Date:  1994-03       Impact factor: 3.466

8.  Fasting adaptation in idiopathic ketotic hypoglycemia: a mismatch between glucose production and demand.

Authors:  Hidde H Huidekoper; Marinus Duran; Marjolein Turkenburg; Mariëtte T Ackermans; Hans P Sauerwein; Frits A Wijburg
Journal:  Eur J Pediatr       Date:  2007-10-13       Impact factor: 3.183

9.  A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome).

Authors:  Joseph Muenzer; James E Wraith; Michael Beck; Roberto Giugliani; Paul Harmatz; Christine M Eng; Ashok Vellodi; Rick Martin; Uma Ramaswami; Muge Gucsavas-Calikoglu; Suresh Vijayaraghavan; Susanne Wendt; Suzanne Wendt; Ana Cristina Puga; Antonio Puga; Brian Ulbrich; Marwan Shinawi; Maureen Cleary; Diane Piper; Anne Marie Conway; Ann Marie Conway; Alan Kimura
Journal:  Genet Med       Date:  2006-08       Impact factor: 8.822

  9 in total
  2 in total

Review 1.  Pre-clinical Mouse Models of Neurodegenerative Lysosomal Storage Diseases.

Authors:  Jacob M Favret; Nadav I Weinstock; M Laura Feltri; Daesung Shin
Journal:  Front Mol Biosci       Date:  2020-04-15

2.  Glycosaminoglycan signatures in body fluids of mucopolysaccharidosis type II mouse model under long-term enzyme replacement therapy.

Authors:  Francesca Maccari; Laura Rigon; Veronica Mantovani; Fabio Galeotti; Marika Salvalaio; Francesca D'Avanzo; Alessandra Zanetti; Federica Capitani; Orazio Gabrielli; Rosella Tomanin; Nicola Volpi
Journal:  J Mol Med (Berl)       Date:  2022-07-11       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.